Prohibits the state, participating ERISA, or any health plan from purchasing referenced drugs for a cost higher than the referenced rate.
Summary
H5860 would create a new chapter in Rhode Island law on prescription drug cost protection. The bill is aimed at limiting what the state, health plans, and any ERISA plan that opts in may pay for certain prescription drugs that are subject to a federal “maximum fair price” under the Inflation Reduction Act. It defines key terms such as “referenced drug,” “maximum fair price,” “health plan,” and “participating ERISA plan,” and makes it unlawful to pay or seek reimbursement above that price during the applicable period, while expressly allowing pharmacy dispensing fees above the drug price.
The bill also requires participating entities to use any savings from the lower drug prices to reduce consumer costs and to report those savings annually to the insurance commissioner, including how the savings were used to promote health equity. It gives the insurance commissioner rulemaking authority, authorizes the attorney general to enforce the chapter, and imposes civil penalties for violations. The bill further prohibits manufacturers or distributors from withdrawing referenced drugs from the Rhode Island market to avoid the pricing limits or from refusing to negotiate in good faith, with penalties of $500,000 or the amount of annual savings, whichever is greater.
Impact
If enacted, H5860 would add a new chapter to Title 21 of the General Laws and directly regulate prescription drug purchasing and reimbursement by state entities and health plans in Rhode Island. It would also create an opt-in framework for ERISA plans, require annual reporting to the insurance commissioner, and impose enforcement mechanisms and penalties on manufacturers and distributors. The bill would affect state purchasing practices, insurers, pharmacy benefit arrangements, and potentially drug manufacturers doing business in the state.
Sentiment
There is no recorded committee transcript or vote history in the provided materials, so no formal legislative debate or recorded sentiment can be measured from the available context. Based on the bill text, the measure is framed as a consumer- and cost-protection proposal intended to reduce prescription drug spending, improve access to medications, and relieve pressure on public and private health costs. The sponsor list suggests support from multiple House members, but the available record does not show opposition or amendments.
Contention
The main points of potential contention are the bill’s price-control approach, its application to health plans and state purchasing, and its enforcement provisions against manufacturers and distributors. Drug manufacturers may object to the prohibition on withdrawing products from the Rhode Island market and the requirement to negotiate in good faith, while insurers and plan administrators may be concerned about compliance, reporting, and savings-allocation requirements. The ERISA opt-in structure may also raise questions about the bill’s interaction with federally regulated employee benefit plans.